Additional information can be found in an online-only appendix at http://diabetes.diabetesjournals.org. 
Type 2 diabetes (T2D) has a substantial genetic component, but the polygenic nature of this disease has complicated the identification of susceptibility genes (1) . We previously reported evidence for linkage of T2D and impaired glucose tolerance (IGT) to chromosome 1q21-q24 (LOD = 2.35, p = 0.0008) in the Old Order Amish (2) that also has been reported in several other populations (3) (4) (5) (6) (7) (8) . Genotyping of multiple SNPs within the region of linkage as part of our linkage disequilibrium (LD) mapping studies in the Amish pointed to a region containing Rho guanine nucleotide exchange factor 11 (ARHGEF11). ARHGEF11 is one of 85 activators of Rho GTPases that play a fundamental role in G protein signaling and thus many aspects of cellular regulation (9, 10) , including betacell apoptosis and insulin secretion (11) (12) (13) , insulin signaling (14) (15) (16) (17) (18) , and lipid metabolism (19, 20) .
We hypothesized that variation in ARHGEF11 may affect insulin secretion and/or action and thus T2D susceptibility. We sequenced the 41 exons, intron-exon boundaries and 1.5 kb of the putative proximal promoter region of ARHGEF11. A total of 39 variants were identified including two non-synonymous (G1456S, R1467H), two synonymous (S694S, N1207N), three in the 5' flanking region, four in the 5'-untranslated region, and one in the 3'-untranslated region; all others were in introns and did not predict any obvious alterations in RNA splicing.
Fifty-two SNPs from among the 39 SNPs identified from sequencing and among validated SNPs in dbSNP covering the entire 132.8 kb region comprising ARHGEF11 and immediately flanking the gene from 22.4 kb upstream of the ATG start site to 1.0 kb downstream of the polyadenylation signal (average density 1 SNP per 2.7 kb) were genotyped in 145 T2D, 148 IGT and 358 normal glucose tolerant (NGT) individuals, and tested for association with T2D and T2D/IGT ( Figure 1 ). All SNPs conformed to HardyWeinberg expectations. Using an additive model, 30 of the 52 SNPs, spanning the entire ARHGEF11 gene, were significantly associated with T2D or T2D/IGT (p = 0.0008 -0.05) ( Table 1 and Figure 1 ). The two SNPs most strongly associated with T2D and T2D/IGT were rs6427340 in intron 2 (p = 0.005 and 0.0008, respectively) and rs12136088 in intron 8 (p = 0.002 and 0.003, respectively). The R1467H variant in exon 39 was more weakly associated with T2D (p = 0.04, OR = 0.66, CI = 0.44 -0.98), with the more common allele (C allele encoding arginine at codon 1467) being the 'risk' allele for T2D. The other two coding region variants (D1456S and S694S) did not show significant association with T2D or T2D/IGT.
The relationship between ARHGEF11 SNPs and quantitative traits was assessed in 754 nondiabetic members of the Amish Family Diabetes Study (AFDS). Eighteen of the 30 T2D/IGTassociated SNPs located from the 5'flanking region to intron 8 were significantly associated with glucose area under the curve (AUC) during a 3-hour oral glucose tolerance test (OGTT)(P < 0.05) (Figure 2 ). These findings in nondiabetic subjects provide additional support for an effect of ARHGEF 11 polymorphism on glucose homeostasis. The R1467H was not associated with glucose AUC among nondiabetic subjects. There was no evidence for association of any SNPs with body mass index (BMI), insulin levels, insulin sensitivity index (ISI), or homeostatic model of insulin resistance (HOMA-IR).
The SNPs within the ARHGEF 11 region were in high linkage disequilibrium (LD) (Figure 1 ). The nine SNPs that were most significantly associated with T2D or T2D/IGT defined five haplotypes (three with frequencies greater than 0.05), accounting for >99% of chromosomes in the sample ( Table 2 ). The TTGTTACCG haplotype was associated with a significantly higher risk of T2D/IGT (p=0.010) while the AGAAGCTTA haplotype was associated with a significantly lower risk of T2D/IGT (p=0.0002) (global p-value for test = 0.006). These same haplotypes were also significantly associated with glucose AUC in the expanded set of nondiabetic subjects (global p-value for test = 0.008) ( Figure 1) .
Our region of linkage on chromosome 1q21-q24 spans approximately 30 Mb and contains at least 450 genes, including many excellent biological candidates. Our initial hypothesis-free LD mapping with more than 500 SNPs across the region led us to ARHGEF11, an activator of Rho GTPases. Although ARHGEF11 itself is not known to play a role in glucose homeostasis, previous studies implicate Rho subfamily G-proteins (e.g., Cdc42 and Rac) in physiological insulin secretion (11) (12) (13) . Furthermore, several recent studies implicated Rho GTPases in insulin signaling through activation of the JNK and p38 MAP kinase pathways (10, 14, 15) .
The dynamic actin rearrangement required for insulinstimulated translocation of glucose transporter 4 (GLUT4) is regulated by at least two distinct signals, one leading to the activation of phosphatidylinositol (PI) 3-kinase (16) and the other to the activation of Rho family small GTPbinding protein TC10 (17) . Finally, a number of enzymes involved in lipid metabolism are influenced by GTPases including PI4P 5-kinase, diacylglycerol kinase and phospholipase D (19, 20) . ARHGEF11 is ubiquitously expressed in various tissues, including liver, muscle and adipose tissue. Together, these data suggest that proteins involved in G protein signaling such as ARHGEF11 may play an important role in glucose homeostasis.
Our current study provides evidence that variation within ARHGEF11 influences risk of T2D/IGT in the Amish. Given the strong LD across ARHGEF11, it is difficult to know which SNPs are the causal genetic variants. In this study, rs6427340 in intron 2 and rs12136088 in intron 8 were most significantly associated with T2D and glucose traits; however the functional consequences of these variants is unclear.
Since we sequenced all exons, it is unlikely that we missed common coding variants, although it is possible that other potentially functional variants, perhaps in more distal regulatory regions or within regions of introns not sequenced may have been missed. R1467H was the only variant encoding an alteration in amino acid sequence that was significantly associated with T2D. However, this variant was not the most significantly associated variant and was not associated with any of the diabetes-related quantitative traits. Interesting, the R1467H substitution was significantly associated with T2D and insulin resistance among the Pima Indians who also have linkage to T2D on chromosome 1q21-q25 (22) . However, contrary to our findings in the Amish, in which the 1467R allele was the risk allele for T2D, the 1467H allele was the risk allele for insulin resistance and T2D in the Pima Indians. Associations with opposite risk alleles in the two populations may suggest that R1467H is not the functional variant but rather is in LD with a true functional variant. Less likely, differences in genetic background or environmental exposures between these populations could modulate the phenotypic expression of the R1467H variant to increase or decrease T2D risk in subjects carrying the same allele. Finally, it is also possible that one or both associations are false positives due to multiple comparisons.
T2D-associated
SNPs in ARHGEF11 did not provide evidence for linkage to T2D/IGT using the same family structures as in our original linkage analysis (2)(data not shown). These findings are consistent with the prevailing idea that there is more than one T2D susceptibility gene on chromosome 1q21-q24 (21) .
Additional genotyping of SNPs in neighboring genes and LD analysis revealed that the T2D/IGT-associated SNPs were in strong LD and constitute a large haplotype block that include one gene and two predicted genes. Indeed, several SNPs in the predicted gene FLJ32884 immediately 3' to ARHGEF11 were associated with T2D and/or T2D/IGT. Thus we cannot rule out the possibility that the functional variant or haplotype is in this gene or even possibly other nearby genes.
In summary, we identified sequence variation in ARHGEF11 that may influence risk of T2D. Further investigation of the role of ARHGEF11 in insulin secretion and signaling and functional studies of the T2D-associated sequence variants will be necessary to more fully understand the mechanisms underlying these associations.
RESEARCH DESIGN AND METHODS

Subjects
The AFDS was begun in 1995 to identify susceptibility genes for T2D and related traits. Details of the AFDS design, recruitment, phenotyping, and pedigree structure have been described previously (23) . Our initial case-control analysis included 145 subjects with T2D, 148 subjects with IGT, and 358 subjects with NGT. NGT subjects included in this analysis were required to be at least 38 years of age at the time of examination in order to increase the probability of their capacity for diabetes resistance. For analysis of diabetes-related quantitative traits, an expanded set on 754 nondiabetic subjects (NGT and IGT) was used. 
Sequence analysis and genotyping
Direct sequencing was used to screen the 41 exons, exon-intron boundaries, and 1.5 kb of the proximal 5' regulatory region of ARHGEF11 for genetic variation in 24 AFDS participants (18 T2D subjects from non-first degree relatives of families providing evidence for linkage of T2D to chromosome 1q21-q24 and 6 NGT subjects). This sequencing set (48 chromosomes) provides 91% power to detect at least one copy of the minor allele for SNPs with allele frequencies ≥ 0.05. Both strands were sequenced on an ABI 3730xl DNA sequencer (Applied Biosystems) and analyzed using Sequencher software (GeneCodes). From SNPs identified by sequencing and from dbSNP, 52 SNPs in ARHGEF11 were genotyped in the full sample. Another 
Real time PCR
RNA was obtained from 12 normal human tissues (Ambion). Realtime RT-PCR was performed using TaqMan primers and probe (assay ID: Hs00207600_m1; Applied Biosystems) on an ABI 7700 Sequence Detection System using standard conditions and cycle times/temperatures. The Taqman endogenous control was human cyclophilin A (PPIA) and data are shown as relative expression units.
Statistical analysis
Because of the extensive relatedness of study subjects in our Amish pedigrees, we tested for associations of SNP genotypes while accounting for the pedigree structure. We evaluated the association between SNP genotype and disease status (T2D versus NGT and T2D/IGT versus NGT) under the additive genetic model using a variance component approach, in which we modeled the probability that the subject was a case or control as a function of the individual's age, gender and genotype, conditional on the correlations in phenotype among relative pairs. Statistical testing was accomplished using the likelihood ratio test. The odds ratio (OR) was computed by comparing the odds of disease between subjects carrying one copy of minor allele and subjects not carrying any copies of the minor allele. The association analyses were carried out using SOLAR as previously described (21) .
In an expanded set of 754 nondiabetic subjects (including 606 NGT and 148 IGT subjects), we also evaluated the effect of genotype on levels of quantitative traits (e.g., BMI, glucose and insulin levels) by comparing mean trait levels across genotypes as previously described (21) . We compared the likelihood of a model in which the trait values were allowed to vary by genotype (unconstrained model) to that in which the genotype effects were constrained to be zero using the likelihoods ratio test. Within each model, we simultaneously estimated the effects of age, sex, and family relationship.
Pairwise LD and haplotype structure were determined using Haploview (24) . Haploscore was used to estimate and compare haplotype frequencies between case and control groups (25) . NCBI location is based on Build 35.1. OR > 1.00 denotes that the minor allele is the risk allele while OR < 1.00 denotes that the major allele is the risk allele. Abbreviations: T2D = type 2 diabetes; IGT = impaired glucose tolerance; NGT = normal glucose tolerance; OR = odds ratio; CI = confidence interval. 
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